ALS Invest 1 B.V. - Jan 6, 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
10%+ Owner
Signature
/s/ Felix-Andre von Coerper
Stock symbol
AMLX
Transactions as of
Jan 6, 2022
Transactions value $
$0
Form type
3
Date filed
5/5/2022, 04:42 PM
Next filing
Jul 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AMLX Series A Preferred Stock Jan 6, 2022 Common Stock 1.13M Direct F1, F2
holding AMLX Series B Preferred Stock Jan 6, 2022 Common Stock 4.83M Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A and Series B preferred stock (collectively the "Preferred Stock") is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Preferred Stock has no expiration date.
F2 The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person.